Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GlycoPEG-GCSF studied in phase I trial

Nov. 13, 2006

Infuse Bone Graft recommended for approval in third indication

Nov. 10, 2006

Oxygent development update

Nov. 10, 2006

Phase II study of Hemopure cleared to continue

Nov. 10, 2006

Novel 5-HT6 antagonist from Suven shows antiobesity properties in animal models

Nov. 9, 2006

CYT009-GhrQb shows no effect on weight loss in obesity study

Nov. 9, 2006

Recent patents describe new antidiabetic agents

Nov. 8, 2006

Duetact now available in U.S.

Nov. 8, 2006

Bremelanotide effective in diabetic and nondiabetic erectile dysfunction patients

Nov. 8, 2006

Recent Novo Nordisk and Roche patents disclose novel treatment strategies for obesity

Nov. 7, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...